CagriSema for High Blood Pressure in People With Obesity
Tests CagriSema in adults with high blood pressure and obesity.
Plain-language title generated from the registry record
Registry title: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Key facts
- Where
- Albany, Amarillo, Austin, Bellaire, Bowling Green, Bristol, Buckley, Canton, Chicago, City of Saint Peters, Clearwater, Concord, Conyers, Costa Mesa, Cumberland, Dallas, Flint, Fullerton, Houston, Indianapolis, Kingsport, Lampasas, Longview, Louisville, Montclair, Morton, Nashville, Norman, North Charleston, Ocala, Orlando, Palm Springs, Portsmouth, Raleigh, Renton, Roswell, San Antonio, San Dimas, Savannah, Shavano Park, Skokie, Spartanburg, Springfield, St Louis, Statesville, Wadsworth, Waterbury, West Des Moines, West Seneca, and Westfield, United StatesSee the 57 sites
- Phase
- Phase 3
Where in United States
- Javara Inc. / Privia Medical Group Georgia LLCAlbany, United StatesNo longer taking part
- Amarillo Med Spec LLPAmarillo, United StatesNo longer taking part
- Texas Diabetes & EndocrinologyAustin, United StatesNo longer taking part
- Texas Diabetes & Endocrinology, P.A._AustinAustin, United StatesNo longer taking part
- Juno Research LLCBellaire, United StatesNo longer taking part
- Graves Gibert ClinicBowling Green, United StatesNo longer taking part
- Holston Medical Group PcBristol, United StatesNo longer taking part
- Northern Pines Hlth Ctr, PCBuckley, United StatesNo longer taking part
- Diab & Endo Assoc of Stark CoCanton, United StatesNo longer taking part
- Great Lakes Clinical TrialsChicago, United StatesNo longer taking part
- StudyMetrix Research, LLCCity of Saint Peters, United StatesNo longer taking part
- Clinical Res Of W Florida IncClearwater, United StatesNo longer taking part
- John Muir Physicians NetworkConcord, United StatesNo longer taking part
- Hope Clin Res & WellnessConyers, United StatesNo longer taking part
- Aurora FDRC Inc.Costa Mesa, United StatesNo longer taking part
- Clinical Res CollaborativeCumberland, United StatesNo longer taking part
- Baylor Jack and Jane HamiltonDallas, United StatesNo longer taking part
- North Texas Endocrine CenterDallas, United StatesNo longer taking part
- Velocity Clin Res, DallasDallas, United StatesNo longer taking part
- Aa Mrc LlcFlint, United StatesNo longer taking part
- Providence Medical FoundationFullerton, United StatesNo longer taking part
- Discovery MM Services, IncHouston, United StatesNo longer taking part
- The Endocrine CenterHouston, United StatesNo longer taking part
- Midwest Inst For Clin ResIndianapolis, United StatesNo longer taking part
- Holston Medical Group.Kingsport, United StatesNo longer taking part
- Radiance Clinical ResearchLampasas, United StatesNo longer taking part
- DCOL Ctr for Clin ResLongview, United StatesNo longer taking part
- Monroe Biomedical Research, LLCLouisville, United StatesNo longer taking part
- Catalina Research Institute, LLCMontclair, United StatesNo longer taking part
- Koch ResearchMorton, United StatesNo longer taking part
- Clinical Research AssociatesNashville, United StatesNo longer taking part
- Lynn Institute of NormanNorman, United StatesNo longer taking part
- Coastal Carolina Res CtrNorth Charleston, United StatesNo longer taking part
- Renstar Medical ResearchOcala, United StatesNo longer taking part
- Florida Institute for Clinical ResearchOrlando, United StatesNo longer taking part
- Desert Oasis Hlthcr Med GroupPalm Springs, United StatesNo longer taking part
- Seacoast Kidney & Htn SpecialistsPortsmouth, United StatesNo longer taking part
- Accellacare_NCRaleigh, United StatesNo longer taking part
- Medication Management, LLCRaleigh, United StatesNo longer taking part
- Rainier Clin Res Ctr IncRenton, United StatesNo longer taking part
- Endocrine Research Solutions, IncRoswell, United StatesNo longer taking part
- Clinical Advancement CenterSan Antonio, United StatesNo longer taking part
- Northeast Clinical Research of San AntonioSan Antonio, United StatesNo longer taking part
- N America Res Inst - San DimasSan Dimas, United StatesNo longer taking part
- Javara Inc./Privia Medical Group Georgia, LLCSavannah, United StatesNo longer taking part
- Consano Clinical Research, LLCShavano Park, United StatesNo longer taking part
- Endeavor HealthSkokie, United StatesNo longer taking part
- Evanston Premier Hlthcr ResSkokie, United StatesNo longer taking part
- Spartanburg Medical ResearchSpartanburg, United StatesNo longer taking part
- SIU MedicineSpringfield, United StatesNo longer taking part
- Amicis Centers of Clinical ResearchSt Louis, United StatesNo longer taking part
- Piedmont Healthcare, Inc.Statesville, United StatesNo longer taking part
- Family Practice Center of Wadsworth Inc.Wadsworth, United StatesNo longer taking part
- Chase Medical Research, LLCWaterbury, United StatesNo longer taking part
- Iowa Diabetes ResearchWest Des Moines, United StatesNo longer taking part
- Southgate Medical Group, LLPWest Seneca, United StatesNo longer taking part
- Great Lakes Medical ResearchWestfield, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07919405
- Record updated
- 5 November 2026
- Original description
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.Read full original descriptionShow less
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.
Inclusion: Male or female (sex at birth); Age 18 years or above at the time of signing the informed consent; Resting in-office SBP of 140-160 mmHg (both inclusive) at screening (V1-Optional/V1) and the Run-in visit. Systolic blood pressure will be calculated as the mean of the second and third consecutive readings of triplicated blood pressure readings collected at 2-minute intervals with the blood pressure monitor provided by the Sponsor; Body mass index greater than or equal to (>=) 30.0 kilograms per metre square (kg/m\^2) at screening; Not receiving Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) or antihypertensive medication or on stable (i.e., same drug(s), dose and dosing frequency) SGLT2i or antihypertensive treatment >= 30 days prior to screening; For participants with Type 2 Diabetes (T2D); The following inclusion criteria apply at screening in addition to the inclusion criteria listed above:; Diagnosed with T2D >= 90 days before screening; Glycated Haemoglobin (HbA1c) 6.5-10.0% (48-86 millimoles per mole (mmol/mol)) (both inclusive) as measured by the central laboratory at screening; Treatment with either lifestyle intervention only, or treatment with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors, glinides, SGLT2i or thiazolidinediones, as a single agent or in combination) according to local label; Treatment with antidiabetic medication should be stable (i.e., same drug(s), dose and dosing frequency) for at least 90 days before screening.
Exclusion: Hospitalisation within the last 90 days before screening for hypertension or hypertensive crisis; A change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records; Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening; Use of any Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin agonists, within 90 days before screening; For participants without T2D; Known secondary hypertension due to renovascular hypertension (renal artery stenosis), primary aldosteronism, Cushing's syndrome, pheochromocytoma, acromegaly, coarctation of the aorta, or any other identifiable cause of secondary hypertension; Currently under medical investigation for any cause of secondary hypertension; Atrial fibrillation at the Run-in visit or history of frequent intermittent or chronic atrial fibrillation; History of type 1 or type 2 diabetes mellitus; Moderate-to-severe anaemia with Hgb lesser than (<) 10.9 grams per decilitre (g/dL) as measured by the central lab at screening; HbA1c greater than or equal to >= 6.5 % (48 mmol/mol) as measured by the central laboratory at screening; Known orthostatic hypotension or orthostatic hypotension at screening (V1-Optional/V1).